Compare Repligen Corporation Common Stock (RGEN) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard High Dividend Yield ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vanguard High Dividend Yield ETF trades at $159.3 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 9× Repligen Corporation Common Stock's market cap, and Vanguard High Dividend Yield ETF is more actively traded (834,323 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| RGEN | VYM | |
|---|---|---|
Market Cap | $11.14B | $100.80B |
Volume | 1,259,263 | 834,323 |
Sector | Health | — |
52-Week High | $194.57 | $167.03 |
52-Week Low | $102.87 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VYM trades at $159.11, down slightly by 0.08% today, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong sector diversification and a 2.42% dividend yield, though recent news highlights competition from alternatives like SCHD and IDV. Support levels are clustered around $157-158, with resistance at $160-161.
Outlook remains mixed; VYM offers steady income but faces pressure from higher-yielding or better-performing peers. Key risks include dividend cuts in holdings like Intel and Walgreens, while institutional sentiment leans cautious due to moderate growth prospects versus competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
